KR102673489B1 - Cxcr2 항체 및 그의 용도 - Google Patents

Cxcr2 항체 및 그의 용도 Download PDF

Info

Publication number
KR102673489B1
KR102673489B1 KR1020197027809A KR20197027809A KR102673489B1 KR 102673489 B1 KR102673489 B1 KR 102673489B1 KR 1020197027809 A KR1020197027809 A KR 1020197027809A KR 20197027809 A KR20197027809 A KR 20197027809A KR 102673489 B1 KR102673489 B1 KR 102673489B1
Authority
KR
South Korea
Prior art keywords
seq
set forth
antibody
cxcr2
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197027809A
Other languages
English (en)
Korean (ko)
Other versions
KR20190123753A (ko
Inventor
찰스 레이 맥카이
레미 마이클 로버트
Original Assignee
모나쉬 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900656A external-priority patent/AU2017900656A0/en
Application filed by 모나쉬 유니버시티 filed Critical 모나쉬 유니버시티
Publication of KR20190123753A publication Critical patent/KR20190123753A/ko
Application granted granted Critical
Publication of KR102673489B1 publication Critical patent/KR102673489B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197027809A 2017-02-27 2018-02-27 Cxcr2 항체 및 그의 용도 Active KR102673489B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900656A AU2017900656A0 (en) 2017-02-27 CXCR2 antibodies
AU2017900656 2017-02-27
PCT/IB2018/000253 WO2018154391A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20190123753A KR20190123753A (ko) 2019-11-01
KR102673489B1 true KR102673489B1 (ko) 2024-06-07

Family

ID=63253562

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197027809A Active KR102673489B1 (ko) 2017-02-27 2018-02-27 Cxcr2 항체 및 그의 용도

Country Status (8)

Country Link
US (1) US11053319B2 (https=)
EP (1) EP3585816A4 (https=)
JP (2) JP7562258B2 (https=)
KR (1) KR102673489B1 (https=)
CN (1) CN110637034B (https=)
AU (1) AU2018224391B2 (https=)
CA (1) CA3054616A1 (https=)
WO (1) WO2018154391A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018224391B2 (en) 2017-02-27 2025-06-12 Monash University CXCR2 antibodies and uses thereof
CN112955463B (zh) 2018-08-01 2024-07-05 赛福伦有限责任公司 抗cxcr2抗体及其用途
US20220332835A1 (en) * 2019-09-04 2022-10-20 Shanghaitech University Anti-cxcr2 antibodies and uses thereof
TWI825687B (zh) * 2021-04-26 2023-12-11 高雄醫學大學 抗ｃｘｃｒ２抗體及其用途
EP4700046A1 (en) * 2023-06-28 2026-02-25 Scripps Korea Antibody Institute Anti-cxcr2 antibody and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060347A1 (en) 2013-04-17 2016-03-03 Morphosys Ag Antibodies targeting specifically human cxcr2
JP2016174611A (ja) 2010-11-08 2016-10-06 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2015169811A2 (en) * 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
WO2018129261A1 (en) * 2017-01-05 2018-07-12 Brown University Methods and compositions relating to anti-chi3l1 antibody reagents
AU2018224391B2 (en) 2017-02-27 2025-06-12 Monash University CXCR2 antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016174611A (ja) 2010-11-08 2016-10-06 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
US20160060347A1 (en) 2013-04-17 2016-03-03 Morphosys Ag Antibodies targeting specifically human cxcr2

Also Published As

Publication number Publication date
JP7562258B2 (ja) 2024-10-07
CA3054616A1 (en) 2018-08-30
US11053319B2 (en) 2021-07-06
AU2018224391A1 (en) 2019-09-19
EP3585816A1 (en) 2020-01-01
US20190016809A1 (en) 2019-01-17
JP2023052023A (ja) 2023-04-11
JP2020508074A (ja) 2020-03-19
WO2018154391A1 (en) 2018-08-30
CN110637034B (zh) 2023-10-10
KR20190123753A (ko) 2019-11-01
AU2018224391B2 (en) 2025-06-12
CN110637034A (zh) 2019-12-31
EP3585816A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
EP2718322B1 (en) Therapeutic antibodies
KR102673489B1 (ko) Cxcr2 항체 및 그의 용도
WO2021180205A1 (zh) Pvrig结合蛋白及其医药用途
WO2021185273A1 (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
US20190352390A1 (en) Antibodies to il-37
EP3464354B1 (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses
CA3131036A1 (en) Cd3 antigen-binding fragment and application thereof
TW202330600A (zh) Fap/cd40 結合分子及其醫藥用途
KR20240039006A (ko) 신규 항-sirpa 항체
CN116981477A (zh) 抗masp2抗体、其抗原结合片段及医药用途
TW202227498A (zh) 新型抗ｃｌａｕｄｉｎ１８抗體
US20240336686A1 (en) Novel multi-specific molecules
CN111295395B (zh) 抗体和使用方法
KR20210007041A (ko) 항-gm-csf 항체 및 이것의 사용
EP4108683A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
WO2022188801A1 (zh) Pd-1结合蛋白及其医药用途
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
WO2026046399A1 (en) Anti-dll3 antibodies and use thereof
JP2026048674A (ja) 免疫グロブリン変異体
HK40082498A (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
WO2023023150A2 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
HK40106257A (zh) 新型抗sirpa抗体
HK40006912A (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses
HK40006912B (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190923

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230707

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240509

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240604

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240604

End annual number: 3

Start annual number: 1

PG1601 Publication of registration